SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics,
Incorporated (Nasdaq: CYTK) announced results from the analyses of
three Phase II clinical trials of ispinesib administered as
monotherapy, one in patients with hepatocellular cancer, one in
patients with melanoma, and one in patients with hormone-refractory
prostate cancer. Ispinesib is a novel small molecule inhibitor of
kinesin spindle protein (KSP), a mitotic kinesin essential for
proper cell division. Ispinesib has arisen from a broad
strategic collaboration between Cytokinetics and GlaxoSmithKline
(GSK) to discover, develop and commercialize novel small molecule
therapeutics targeting human mitotic kinesins for applications in
the treatment of cancer and other diseases. All three
clinical trials were sponsored by the National Cancer Institute
(NCI).

A Phase II clinical trial designed to evaluate the safety and
efficacy of ispinesib in the treatment of patients with locally
advanced, recurrent or metastatic hepatocellular cancer was
recently completed. In Stage 1 of this two-stage clinical
trial, 15 patients received ispinesib as monotherapy at 18 mg/m2 as
a 1-hour intravenous infusion every 21 days. The trial s
primary endpoint was objective response as determined using the
Response Evaluation Criteria in Solid Tumors (RECIST)
criteria. This trial was designed to require at least 1
confirmed partial or complete response out of 15 evaluable patients
in Stage 1 in order to proceed to Stage 2. The best overall
response was stable disease seen in 7 of the 15 patients
treated. In this clinical trial, ispinesib did not satisfy
the criteria for advancement to the second stage and therefore
recruitment to Stage 2 was not opened. The toxicity
profile was consistent with other previously reported Phase II
clinical trials of ispinesib. A manuscript is being
prepared.

(Date:3/3/2015)... 3, 2015 Based on its recent ... & Sullivan recognizes Neopeutics, Inc. with the 2015 ... Leadership. Neopeutics has demonstrated a remarkable ability to ... easily adaptable set of drug discovery instruments. It ... failing compounds in the early stages of the ...

... GlaxoSmithKline (NYSE:,GSK), one of the world,s largest ... order to purchase bulk H5N1 antigen for the ... announced the,start of the first North American pre-pandemic ... HHS Order The company has received ...

... N.J., Aug. 6 MicroDose Technologies,Inc., a ... company,today announces top line results from a ... product. MicroDose, through its joint venture with ... highly efficient, rapid acting,insulin inhaler, based upon ...

(Date:3/3/2015)... (PRWEB) March 04, 2015 The report ... on the therapeutic development for Alopecia. Alopecia is the ... the two main types of alopecia. Causes for alopecia ... Symptoms of alopecia may include male pattern hair loss, ... hair. Alopecia can be classified as focal or diffuse ...

(Date:3/3/2015)... (PRWEB) March 03, 2015 The first ... the National Sleep Foundation. The event brings recognition to ... over. , According to the Centers for ... problems of one form or another. Too little or ... risk of physical illness and depression, and even a ...

(Date:3/3/2015)... 2015 The combinatorial, multi-gene GeneSight ... treatment outcomes for patients with depression, and their ... the individual genes that comprise the test, according ... Mayo Clinic and Assurex Health, and published online ... proprietary technology of the GeneSight Psychotropic test is ...

(Date:3/3/2015)... 2015 The North America ... grow from $1,224.6 million to $1,694.6 million, ... and 2019. , Browse through the TOC ... for an analysis of industry trends and ... and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html , An ...

... Through a new advertising campaign being launched in Memphis today, ... and prevention. Cervical cancer is caused by high-risk types ... the only FDA-approved HPV test, has selected Memphis as a ... ad for the digene HPV Test on local ...

... Family, Encourage Charitable Giving , BOSTON, Feb. 9 ... today launched the ,Light a Candle, program -- offering consumers ... their loved ones. Visitors can now light candles or ... million current and historical obituaries available on the popular national ...

... Television Week for providing "vital information" to viewers, ... program that tells the compelling and inspirational stories of real ... Denver, CO; Albany, NY; Austin, TX; Salt Lake City, UT; ... the program now airs on nearly 260 television stations across ...

... MINNEAPOLIS, Feb. 9 ARKRAY USA, Inc., the 5th ... clearance from,the U.S. Food and Drug Administration for the ... This new system requires no coding, displays results ... size, and was developed to use the same,affordable test ...

... to learn about Heart Failure-how to prevent it and to ... Week February 8-14, 2009 Heart Failure Society of ... Available at www.abouthf.org NEW YORK, ... for February 8-14. This is a time for ...

The STALIF stand-alone anterior lumbar fusion cage is the latest product development from Surgicraft. STALIF is the natural evolution of the Hartshill Horseshoe, which has over 10 years clinical suc...

... Computerized Vision Tester offers the latest ... the many features of our complete ... delegating the refraction, electronic data collection, ... an incredible interest in this product! ...